Steve Chesney
Stock Analyst at Redburn Atlantic
(2.06)
# 2,918
Out of 4,902 analysts
53
Total ratings
58.06%
Success rate
0.12%
Average return
Main Sectors:
Stocks Rated by Steve Chesney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $545 | $462.62 | +17.81% | 1 | Jun 27, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $77 → $54 | $47.90 | +12.73% | 10 | Feb 6, 2024 | |
| BIIB Biogen | Maintains: Neutral | $282 → $275 | $128.81 | +113.49% | 7 | Aug 8, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $167 → $170 | $163.38 | +4.05% | 8 | Aug 4, 2023 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $600 | $519.37 | +15.52% | 7 | Aug 2, 2023 | |
| ZTS Zoetis | Reiterates: Overweight | $225 | $150.12 | +49.88% | 2 | Jun 14, 2023 | |
| MRK Merck & Co. | Maintains: Overweight | $127 → $129 | $81.59 | +58.11% | 5 | May 1, 2023 | |
| ABBV AbbVie | Maintains: Neutral | $157 → $154 | $191.92 | -19.76% | 5 | Feb 10, 2023 | |
| PFE Pfizer | Maintains: Neutral | $50 → $46 | $24.57 | +87.26% | 4 | Feb 1, 2023 | |
| AMGN Amgen | Maintains: Underweight | $190 → $182 | $297.77 | -38.88% | 4 | Aug 9, 2022 |
Vertex Pharmaceuticals
Jun 27, 2024
Initiates: Buy
Price Target: $545
Current: $462.62
Upside: +17.81%
Bristol-Myers Squibb Company
Feb 6, 2024
Downgrades: Neutral
Price Target: $77 → $54
Current: $47.90
Upside: +12.73%
Biogen
Aug 8, 2023
Maintains: Neutral
Price Target: $282 → $275
Current: $128.81
Upside: +113.49%
Johnson & Johnson
Aug 4, 2023
Maintains: Neutral
Price Target: $167 → $170
Current: $163.38
Upside: +4.05%
IDEXX Laboratories
Aug 2, 2023
Downgrades: Neutral
Price Target: $600
Current: $519.37
Upside: +15.52%
Zoetis
Jun 14, 2023
Reiterates: Overweight
Price Target: $225
Current: $150.12
Upside: +49.88%
Merck & Co.
May 1, 2023
Maintains: Overweight
Price Target: $127 → $129
Current: $81.59
Upside: +58.11%
AbbVie
Feb 10, 2023
Maintains: Neutral
Price Target: $157 → $154
Current: $191.92
Upside: -19.76%
Pfizer
Feb 1, 2023
Maintains: Neutral
Price Target: $50 → $46
Current: $24.57
Upside: +87.26%
Amgen
Aug 9, 2022
Maintains: Underweight
Price Target: $190 → $182
Current: $297.77
Upside: -38.88%